Marty Chilberg
Contributor since: 2010
Company: Chilberg advisory services
Latest Articles
Spark Therapeutics: This Appears To Be A Dip Worth Buying
Crispr: First Look At June 2018 Updates
Sangamo: First Look At June 2018 Results
BioMarin: Gene Therapy Pipeline Driving Valuation Upside
Netflix Content Wars: Be Careful Out There
Microsoft Overvaluation Concerns: DéJà Vu All Over Again
Genomic Medicine Q2 2018: Do Earnings Matter?
Sangamo: Foundational Platform's Path To Clinical Validation
Sangamo Clinical Trials Dosing Recap
Genomic Medicine: Is The Platform The FDA Product?
Editas: The Most Comprehensive CRISPR Platform - But At What Cost?
Voyager: A Leader In Neurological Gene Therapy Receives RMAT Designation
Gilead Oncology CAR T-Cell Therapies Outlook Compelling
Crispr Therapeutics: Beware Of Articles Minimizing The Clinical Hold Risk
Crispr On Hold While Sangamo Accelerates
Cellectis: Will Focus On Universal CAR-T Payoff?
Crispr Therapeutics: Clinical Debut Sets Up Round 1 Of Editing Battle Royale
bluebird bio: Gene Therapy Best In Class
Genomic Medicine: Catch The Gene Therapy Wave
Sangamo: The Secondary Was Ill-Timed Or Not
Sangamo: 3 Waves Of Pipeline Expansion
Sangamo Therapeutics: Engineering Genomic Solutions For Rare Diseases
Adobe: Digitally Transformed In The Cloud
The Beginning Of The End Of Non-GAAP Earnings
Cloud Tracks: Q2 2017
Capital Allocation Review: Dividends And Buybacks For IBM, Intel And Microsoft
Microsoft: The Leader Of The Cloud
Digital Transformation: Are Your Investments Disrupting Or At Risk?
Microsoft: Building The Essential Technologies Of The Future
Sequenom: The Last Chapter Is A Head Scratcher
NIPT Poised For Average Risk Inflection Point
NIPT: The Poster Child For Liquid Biopsy